// App-Quantinova.ai

: Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS

Researchers

Presenter

  • Dave Singh

Principal Investigators

  • Klaus F Rabe

  • Fernando J Martinez

  • Martin Jenkins

  • Mehul Patel

  • Paul Dorinsky

Medical Centers

  • Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

  • Astra Zeneca, Cambridge, United Kingdom

  • Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States,

  • LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany,

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Seebri Breezhaler

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02465567

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved